News & Press Releases
Join our Newsletter
To receive News as it is released, please sign up.
December 6, 2021
Former KCI (Acelity), 3M and Siemens Healthcare Vice President Nils Windler joins Spectral MD. See more...
November 18, 2021
The IRB-approved multi-center study enroled a total of 150 adult subjects and was executed successfully and on schedule across six clinical sites in the U.S. The training study with data from all study subjects is expected to complete in December 2021. See more...
November 16, 2021
The results of the first multi-center study using Spectral MD's burn imaging technology include 124 adult and pediatric participants. In adult participants, the performance with cross-validation from the AI model for identification of non-healing burn regions showed 92% accuracy, an improvement on the previously reported accurarcy of 91% for the DeepView® Wound Imaging Solution in early healing assessment of adults. In pediatric patients, the AI performance showed 88% accuracy, underlining how the technology is responding with significant reliability to variability in the study population.
October 20, 2021
Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces the appointment of Stifel Nicolaus Europe Limited as Joint Broker alongside SP Angel Corporate Finance LLP, the existing Broker and Nominated Adviser, with immediate effect.
September 13, 2021
Spectral MD has achieved all the project milestones it set to be achieved by this time in 2021 and has achieved other important milestones ahead of schedule, including early receipt of increased U.S. Government grant funding of c. US $20 million post-IPO and progress on new burn and DFU patient studies.
September 7, 2021
Wensheng Fan, Chief Executive Officer, and Wan Lung Eng, Chief Financial Officer, will provide a live presentation relating to the Company’s interim results via the Investor Meet Company platform on Monday, 13 September at 16:30hrs BST.
September 6, 2021
This contract option funding of $18.8 million under Option 1B of Spectral MD’s current contract with BARDA follows the $20.6 million awarded under Option 1A which was exercised by BARDA in March 2021 to execute the first stage of the clinical training study at five sites to train the DeepView® AI algorithm.
August 9, 2021
Spectral MD welcomed physicians, clinical coordinators, and researchers from five clinical candidate sites across the United States to the kick-off event. Over the two-days, Spectral MD showcased its next generation, user-friendly DeepView® technology to physicians, clinical coordinators, and researchers from the five candidate sites.
July 15, 2021
TR-1: Standard form for notification of major holdings.
June 24, 2021
This Contract will support Spectral MD in advancing a new, multispectral imaging ("MSI") sensor intended to enable the development of a fully handheld version of DeepView™, Spectral MD's existing AI and MSI technology for early burn wound healing assessment, in a far-forward military environment.
June 22, 2021
Oversubscribed Placing for gross proceeds of £11.3 million (c.US$16 million). Click to the summary and highlights here.
June 16, 2021
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.
THESE SECURITIES WILL BE OFFERED ONLY OUTSIDE OF THE UNITED STATES TO NON-U.S. PERSONS, PURSUANT TO THE PROVISIONS OF REGULATION S OF THE U.S. SECURITIES ACT OF 1933, AS AMENDED. THESE SECURITIES WILL NOT BE REGISTERED UNDER THE SECURITIES ACT, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS.
June 7, 2021
Wound care AI company, focused on predictive analytics for faster treatment decisions to seek admission to AIM and raise funding through an IPO.